Sac-TMT meets OS endpoint in Phase 3 gastroesophageal cancer trial
The TROP2-directed ADC is the first to improve overall survival in this pretreated population, but it missed progression-free survival and the objective response rate benefit was not formally tested.
. 2-minute read.

Merck said in a press release that its investigational TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT), licensed from Kelun-Biotech, met the primary overall survival endpoint in the Phase 3 TroFuse-015 trial. The randomized, open-label, global study enrolled 473 people with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma that had progressed after at least two earlier lines of systemic therapy. Participants were randomized to sac-TMT or to physician's choice of trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel. In the final analysis, patients assigned sac-TMT lived significantly longer than those assigned physician's choice. The results were announced in a company press release.
The conjugate carries a belotecan-based topoisomerase I inhibitor and uses a bifunctional linker that is designed to increase payload delivery to tumor cells while reducing loss in the bloodstream. In many common cancers, TROP2 is overexpressed on tumor cells relative to healthy cells. Merck stated that the survival benefit appeared across patient subgroups whether or not their tumors expressed TROP2. However, sac-TMT did not meet the secondary endpoint of progression-free survival as assessed by blinded independent central review. The objective response rate appeared higher with sac-TMT than with physician's choice, but this was a nominal gain and was not formally tested under the study's statistical plan. Side effects were consistent with those seen in earlier sac-TMT trials, and no new safety concerns were identified.
Marjorie Green, Merck Research Laboratories' head of oncology clinical development, said in the release that sac-TMT is the first TROP2-directed ADC to improve overall survival over physician's choice in a global Phase 3 trial for advanced gastroesophageal adenocarcinoma, showing its promise in a difficult-to-treat cancer.
Merck plans to present the data at an upcoming medical meeting and discuss them with regulators. TroFuse-015 is the second positive Phase 3 result from the TroFuse program, which includes 18 global Phase 3 studies across several cancers. Fourteen of those studies, including TroFuse-015, are pursuing first-in-class opportunities. Sac-TMT was developed by Kelun-Biotech, and Merck holds exclusive rights outside Greater China.
BioSpace reported Friday that neither Merck nor Kelun-Biotech shared the efficacy data behind the survival win. RBC Capital Markets analysts wrote in a note that overall survival is still the standard outcome in these settings and that a split between progression-free survival and overall survival is not unheard of, particularly with immunotherapies. The same outlet added that sac-TMT is already approved for four indications in China, and that US regulators are reviewing it under priority review for previously treated endometrial cancer; a decision is due by June 2027. In October, sac-TMT reduced the risk of death by 32% compared with chemotherapy in advanced or recurrent endometrial cancer in the Phase 3 TroFuse-005 trial.
Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.